Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Oncothyreon Rises on New Cancer Therapy Study

By Pharmaceutical Processing | September 25, 2013

Shares of Oncothyreon climbed Wednesday after the company said its partner Merck Serono will run another late-stage trial of an experimental cancer therapy.

Oncothyreon said Merck Serono will study the drug as a treatment for advanced and inoperable non-small lung cancer in patients whose disease is stable after at least two rounds of platinum-based chemotherapy and radiation treatment. It will be designed to measure how long patients live after treatment.

Oncothyreon Inc. shares rose 39 cents, or 21.7 percent, to $2.19 in morning trading Wednesday. They are xx percent below their 52-week high of $5.74 set almost a year ago. They traded as low as $1.55 in June.

The Seattle company Is now calling the therapy tecemotide. It was previously called Stimuvax and L-BLP25. Tecemotide is designed to work by stimulating the body’s immune system so that it can identify and destroy cancer cells. It is the most advanced of Oncothyreon’s experimental drugs. The company doesn’t have any products on the market.

In December Oncothyreon said patients who were treated with tecemotide did not live significantly longer than patients who were given a placebo. However the company said in May that patients who had received chemotherapy and radiation appeared to live longer after treatment with tecemotide: it said patients who received that regimen survived for 30.8 months, compared to 20.6 months for patients who received chemotherapy, radiation and a placebo. The new trial will include only patients who received those treatments.

Merck Serono is a unit of German company Merck KGaA, and it licensed the drug from Oncothyreon.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE